Last reviewed · How we verify
NCT03519022: BED IN 35
Behavioral Effects of Drugs: Inpatient (35)
EARLY_PHASE1 trial testing Cocaine in Cocaine Use Disorder in 9 participants. Completed in 31 May 2019.
31 May 2019
Quick facts
| Lead sponsor | Craig Rush |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 9 |
| Start date | 1 June 2018 |
| Primary completion | 31 May 2019 |
| Estimated completion | 31 May 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cocaine (COCAINE) — full drug profile →
- Placebo oral capsule
- Methylphenidate (methylphenidate) — full drug profile →
Conditions studied
- Cocaine Use Disorder — all drugs for Cocaine Use Disorder →
Sponsor
Craig Rush
Who can join
Adults 18 to 55, any sex, with Cocaine Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will determine the influence of methylphenidate (Metadate®) and duloxetine (Cymbalta®), alone and in combination, on the reinforcing, subjective and physiological effects of cocaine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03519022
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cocaine
Trials testing the same drug.
- NCT05809453 — Intranasal Cocaine and Temperature Regulation During Exercise · Phase 1, PHASE2 · completed
- NCT05019430 — Cocaine and Zolmitriptan · EARLY_PHASE1 · completed
- NCT03937986 — Suvorexant and Cocaine · EARLY_PHASE1 · completed
- NCT03954938 — Behavioral Effects of Drugs (Inpatient): 38 · EARLY_PHASE1 · terminated
- NCT02383043 — Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer · EARLY_PHASE1 · completed
Other recruiting trials for Cocaine Use Disorder
Currently open trials in the same condition.
- NCT07227948 — Repurposing Semaglutide for the Treatment of Cocaine Use Disorder · Phase 2 · recruiting
- NCT07086794 — Cocaine and Pentoxifylline (BED IN 47) · EARLY_PHASE1 · recruiting
- NCT06050304 — CRACK-TARGET 1: Descriptive Study of Observed Behavioral Sensitization and Expectations · NA · recruiting
- NCT07091877 — Cocaine Cue-reactivity Incubation Study · NA · recruiting
- NCT05986578 — Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder · NA · recruiting
Other Craig Rush trials
Trials by the same sponsor.
- NCT04178993 — Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine] · Phase 1 · completed
- NCT03575403 — Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate) · Phase 1 · completed
- NCT03438539 — Brief Online Interventions for Alcohol Use · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03519022 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Craig Rush
- Last refreshed: 25 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03519022.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing